These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22301192)

  • 1. Novel agents for the treatment of HIV-2 infection.
    Peterson K; Rowland-Jones S
    Antivir Ther; 2012; 17(3):435-8. PubMed ID: 22301192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
    Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    McKinnell JA; Saag MS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
    Férir G; Palmer KE; Schols D
    Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
    Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
    AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
    Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
    AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of viral entry.
    Melby T; Westby M
    Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
    Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
    Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.